Part B Drug Rebate Ideas Not Drawing CMS Attention, Despite OIG Prodding
This article was originally published in The Pink Sheet Daily
Executive Summary
The HHS Office of Inspector General finds Medicare Part B could have saved $3.1 billion on 60 of the costliest drugs by applying Medicaid-level rebates, which the office says “warrants further deliberation.” But noting Part B drug rebates are not actively under consideration by the administration or Congress, CMS says it will not devote resources to examining the issue.